Morning, Marco — hope the floor was merciful. It's July 1, so the Florida
laws you'd been tracking for weeks are live as of today, including the two that touch your
world (memory-care ALF licensing and PBM reform). The clinical wires are quiet — no new
guideline drops in the last 48 hours — so today leans on the calendar, the Mets fire sale,
and a debate that will shape what your elderly admits pay at the pharmacy for years. Coffee,
then sleep.
A · Top Stories
Confirmed-fresh, last 48 hours
Update · Florida
The July 1 Florida laws you flagged are now in effect
About 140 new laws took effect today with the state's fiscal year. Two you'd
been watching are live: the strengthened memory-care assisted-living licensure standards and
the pharmacy-benefit-manager (PBM) reform package. The batch also includes a handful of
health-adjacent odds and ends — removal of the $1,500 cap on upfront chiropractic payments,
and recognition of certain gold and silver coins as legal tender for debts incurred on or
after today.
Why it matters to you: the ALF memory-care changes affect where
and how your dementia patients get placed on discharge, and the PBM reform reshapes formulary
and pricing dynamics your patients hit at the counter. Nothing changes your admitting workflow
overnight, but case management will feel the ALF piece first.
Talking point: worth a two-minute check-in with case management this week on
whether the new memory-care ALF standards shift any of your usual discharge destinations.
CBS Miami overview ·
Full list
Update · Mets
Mets are officially in teardown mode heading into the deadline
On the last day of June the Mets sat at roughly 34-48 — 15 games under, buried in
the NL East cellar and about 9.5 back in the wild-card race despite carrying the league's
largest cash payroll. The David Peterson-to-the-Cubs deal (for 1B/DH prospect Cole Mathis)
reads as the opening move of a full sell-off before the Aug. 3 deadline. Luke Weaver (elite
setup year, controlled through 2027), Freddy Peralta, and Brooks Raley are the obvious next
chips. There's even a tanking wrinkle: finishing with a top-six pick would protect their draft
slot from the luxury-tax penalty.
Storyline to follow: whether Weaver — the most valuable trade piece — moves
first, and what the return says about the front office's timeline.
CBS Sports ·
MLB.com
Update · World
US–Iran ceasefire is fraying at the edges
The June 17 ceasefire memorandum is under real strain: over the past several days
the US struck Iranian missile, drone, and radar sites, the IRGC said it hit US positions in the
Gulf in retaliation for an Iranian drone attack on a cargo ship near the Strait of Hormuz, and
VP Vance warned "violence will be met with violence." The tell to watch is whether the Doha
technical talks actually convened this week or slipped.
Al Jazeera (Marco's preferred source for this beat).
B · The Debate
One live argument, both sides steelmanned · 7-day window
Should Medicare's drug price negotiation program become a permanent, codified rule?
Why it's live right now: On June 16 CMS proposed a rule
(CMS-4215-P) that would convert the Inflation Reduction Act's drug-price negotiation program
from year-by-year guidance into permanent regulation, starting with price-applicability year
2029. The comment period runs through Aug. 17, so both sides are making their case now.
For — lock it in
Predictability is the point: a codified framework ends the annual scramble and cements
savings that already cut out-of-pocket costs on the first ten Part D drugs by roughly half.
AARP's Nancy LeaMond frames medications as "a lifeline" for older adults
"stretched to the breaking point," and warns drug makers are "spending millions to weaken
this law." CMS Administrator Mehmet Oz pitches the rule as moving "from
annual updates to a permanent, predictable framework" that "puts patients first" while
still protecting the innovation pipeline.
AARP ·
CMS
Against — don't cement it
Making the program permanent, the industry argues, hard-wires what is effectively
government price-setting into law and blunts the return that funds high-risk R&D —
especially for small-molecule drugs hit earlier in their life cycle. PhRMA
and industry analysts contend a codified framework compounds the chilling effect on future
cures and shifts investment away from the therapies today's seniors will need tomorrow.
Pharmaceutical Commerce ·
PharmExec
Where it might land: comments close Aug. 17; expect litigation
threats either way. Worth noting the empirical dispute is unsettled — a
FREOPP analysis
of round one found the hit to R&D smaller than industry warnings predicted.